Venous thromboembolic events · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Venous thromboembolic events Duration of hospital stay (whole population) · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Arterial thromboembolic events Post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FXIII: Prophylactic trials: intervention showed no clear difference in arterial thromboembolic events Up to 5 to 7 weeks post‐operatively compared with inactive control (low certainty).
3 findings from 1 review
RR 0.67 [0.28, 1.62]
2 studies · 282 participants
Low
RR 3 [0.14, 66.53]
1 study · 22 participants
Low
RR 0.2 [0.01, 3.97]
1 study · 50 participants
Very low
All‐cause mortality In‐hospital mortality up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality In‐hospital mortality up to 30 days… compared with inactive Control (low certainty).
1 finding from 1 review
Venous thromboembolic events · the prevention and treatment of bleeding in patients without haemophilia
FXIII: Prophylactic trials: intervention showed no clear difference in venous thromboembolic events ‐ Up to 5 to 7 weeks post‐operatively compared with inactive control (low certainty).
2 findings from 1 review
Venous thromboembolic events Up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FXIII: Prophylactic trials: intervention showed no clear difference in venous thromboembolic events Up to 30 days post‐operatively compared with inactive control (low certainty).
1 finding from 1 review
All‐cause mortality Up to 6 weeks post‐natally · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
All‐cause mortality Up to 28 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 46 days post‐operatively compared with inactive Control (high certainty).
1 finding from 1 review
All‐cause mortality Up to 7 days post‐operatively or hospital discharge · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
All‐cause mortality Up to 28 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
2 findings from 1 review
Venous thromboembolic events Up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Arterial thrombotic events Up to 4 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Intervention not reported
UCVA of 20/20 or better at 12 months post treatment · adult participants (≥ 18 years) with myopia
The intervention showed no clear difference in UCVA of 20/20 or better at 12 months post treatment (low certainty).
1 finding from 1 review
RR 0.98 [0.92, 1.05]
Studies not reported
Low
Intervention not reported
Within ± 0.50 D of target refraction at 12 months post treatment · adult participants (≥ 18 years) with myopia
The intervention showed no clear difference in within ± 0.50 D of target refraction at 12 months post treatment (low certainty).
1 finding from 1 review
RR 0.93 [0.84, 1.03]
Studies not reported
Low
Intervention not reported
Loss of 1 or more lines of BSCVA at 12 months post treatment · adult participants (≥ 18 years) with myopia
It is very uncertain whether the intervention changes loss of 1 or more lines of BSCVA at 12 months post treatment (very low certainty).
1 finding from 1 review
RR 3 [0.13, 71.96]
Studies not reported
Very low
Intervention not reported
Mean spherical equivalent at 12 months post treatment · adult participants (≥ 18 years) with myopia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Participants cured or improved · Adults with overactive bladder (OAB)
Electrical stimulation probably leads to higher participants cured or improved compared with placebo or sham treatment (moderate certainty).
1 finding from 1 review
Participants with improvement in urgency urinary incontinence · Adults with overactive bladder (OAB)
Electrical stimulation showed no clear difference in participants with improvement in urgency urinary incontinence compared with placebo or sham treatment (low certainty).
1 finding from 1 review
OAB‐related quality of life · Adults with overactive bladder (OAB)
1 finding from 1 review
Adverse effects · Adults with overactive bladder (OAB)
Electrical stimulation showed no clear difference in adverse effects compared with placebo or sham treatment (low certainty).
1 finding from 1 review